Quality Medical Research | Nashville Office

Research site

About

Quality Medical Research is a clinical research center located in the Nashville metro area. We are dedicated to conducting innovative clinical studies addressing a wide spectrum of common diseases. Our primary mission is to provide access to healthcare by offering affordable medications and treatments that meet the needs of patients from diverse backgrounds. Whether you are a sponsor for clinical trials, a potential participant, or an industry expert, we encourage you to discover more about our organization.

Location

330 Wallace Rd Suite 103, Nashville, Tennessee, United States of America

Website

https://thegidocs.com/research/

Site insights

Top conditions

Top treatments

Upadacitinib

ABT-494

Selonsertib

Filgotinib

Relamorelin

Firsocostat

LY3841136

Cilofexor

Semaglutide

DCV

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Christina Stanley

Verified by this site

Active trials

15 of 61 total trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting

Crohn's Disease

Drug: Placebo for Upadacitinib

Drug: Upadacitinib

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling

Overweight

Obesity

Drug: LY3305677

Drug: LY3549492

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety...

Enrolling

Overweight and Obesity

Obesity

Drug: Placebo

Drug: LY3305677

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safet...

Enrolling

Overweight and Obesity

Obesity

Drug: Placebo

Drug: LY3841136

Locations recently updated

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. (AFFIRM)

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Enrolling

Crohn's Disease

Drug: Placebo for risankizumab

Drug: Risankizumab SC

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active ulcerative col...

Enrolling

Ulcerative Colitis

Drug: IV Placebo

Drug: SC Placebo

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) (U-ACHIEVE)

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting

Ulcerative Colitis (UC)

Drug: Placebo

Drug: Upadacitinib (ABT-494)

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with...

Enrolling

Overweight

Obesity

Drug: Placebo

Drug: LY3549492

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136...

Enrolling

Overweight

Obesity

Drug: Placebo

Drug: LY3841136

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis (SELECTIONLTE)

The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy...

Active, not recruiting

Ulcerative Colitis

Drug: Filgotinib

Drug: Placebo

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non al...

Active, not recruiting

Non-alcoholic Steatohepatitis

Drug: Placebo (NNC0194-0499)

Drug: NNC0174 0833 placebo

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (ESSENCE)

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Active, not recruiting

Non-alcoholic Steatohepatitis

Drug: Placebo

Drug: Semaglutide

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Active, not recruiting

Ulcerative Colitis

Drug: ABBV-668

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis (SWIFT)

The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compar...

Enrolling

Ulcerative Colitis

Drug: GS-1427

Drug: Placebo-to-match GS-1427

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (WAYFIND)

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting

Nonalcoholic Steatohepatitis

Drug: Cilofexor (CILO)/Firsocostat (FIR)

Drug: PTM SEMA